Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation (Q83426716)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 February 2012

Language	Label	Description	Also known as
English	Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation	scientific article published on 02 February 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Hans-Ulrich Häring

4

object named as

Hans-Ulrich Häring

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Martina Guthoff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Barbara Schmid-Horch

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Katja C Weisel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Alfred Königsrainer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Nils Heyne

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

2 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Transplant Immunology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

171-175

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Rituximab and intravenous immune globulin for desensitization during renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Acute humoral rejection in a lung recipient: reversion with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

HLA antibody specification using single-antigen beads--a technical solution for the prozone effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Transplant glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Protective immunity remains intact after antibody removal by means of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2012.01.002

7 January 2021

Identifiers

10.1016/J.TRIM.2012.01.002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326708%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83426716&oldid=2083760601"